Skip to main content
Caplight Logo









Cogentis Therapeutics

Cogentis Therapeutics

Private
Columbia, MarylandHealthcare & Life Scienceshttps://cogentistherapeutics.com/

Last Round

Grant

Apr 30, 2020

Total Funding Raised

$188,193

Company Overview

Cogentis Therapeutics is a biotechnology company that develops disease-modifying therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and frontotemporal dementia.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

neurodegenerative diseasepeptide therapeuticdrug discoverybiotechCDK5Alzheimer's researchParkinson's treatmentpreclinical developmentdisease-modifying therapybiotech startupdrug pipelinepharma licensingneuroscience

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cogentis Therapeutics Comparables

Compare Cogentis Therapeutics with similar companies based on industry and business-model similarity.

Cogentis Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
4M Therapeutics
88%
Teitur Trophics
80%
Perha Pharmaceuticals
71%

Cogentis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 30, 2020
AcceleratorMay 21, 2015

Key People

Founding team and executive leadership

Kent Werner

Co-founder and CEO

Founding Team

Cogentis Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 2, 2026

    Monthly visitors increased 349% MoM.

  • May 21, 2015

    Received funding from MassChallenge Israel and The Center for Advancing Innovation.

Cogentis Therapeutics Filings

Explore SEC and related filing metadata, where available.

Cogentis Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cogentis Therapeutics's valuation, stock price, and market status.

Is Cogentis Therapeutics a public or private company?

Cogentis Therapeutics is a private company.

What is the current stock price of Cogentis Therapeutics?

Cogentis Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Cogentis Therapeutics worth (valuation)?

Valuation information for Cogentis Therapeutics is not publicly available.

Can I buy Cogentis Therapeutics stock?

Cogentis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cogentis Therapeutics's last funding round?

Cogentis Therapeutics's most recent funding round was Grant on April 30, 2020.

Who are the main investors in Cogentis Therapeutics?

Key investors in Cogentis Therapeutics include Alzheimer's Drug Discovery Foundation.

Will Cogentis Therapeutics IPO soon?

No public IPO plans have been announced for Cogentis Therapeutics.

How can I track Cogentis Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cogentis Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersColumbia, Maryland
Employee Range4
Year Founded2015
Last FundingApr 30, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?